Ebglyss (Lebrikizumab-lbkz)
Ebglyss (Lebrikizumab-lbkz
- Medicine Name: Ebglyss
- API: Lebrikizumab-lbkz
- Dosage Form & Strength: Injection: 250 mg/2 mL in a single-dose prefilled pen and prefilled pen syringe with needle shield
- Manufactured By: Eli Lilly and Company
Ebglyss (lebrikizumab-lbkz) is an interleukin-13 antagonist used for the treatment of adults and pediatric patients aged 12 years and older who weigh at least 40 kg with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. This medicine can be used with or without topical corticosteroids.
Recommended Dosage: The recommended dosage of lebrikizumab-lbkz starts with 500 mg (two 250 mg injections) administered by subcutaneous (SC) injection at Week 0 and Week 2. Afterward, 250 mg is administered every two weeks until Week 16 or until a clinical response is achieved. The maintenance dosage is 250 mg every four weeks.
Before starting treatment, complete all age-appropriate vaccinations according to current immunization guidelines. If a dose is missed, take it immediately and continue regular dosing at the scheduled time.
- Patients receiving treatment with Ebglyss 250 mg/2 mL injection may experience hypersensitivity reactions, including rash, urticaria, and in rare cases, anaphylaxis. It is crucial to monitor for such reactions and discontinue if necessary. Patients with known allergies to monoclonal antibodies should be carefully evaluated.
- This therapeutic drug has been associated with an increased risk of conjunctivitis and keratitis. Patients should be monitored for any signs and symptoms of eye irritation or infection, and appropriate treatment should be provided if ocular symptoms arise during the course of therapy.
- Treatment with this drug may reduce the immune response to parasitic (helminth) infections. Patients with existing helminth infections should receive treatment before starting Ebglyss. Continuous monitoring for parasitic infections is advised during therapy, especially in endemic areas.
- Live vaccines should be avoided during treatment with lebrikizumab-lbkz 250 mg/2 mL. Non-live vaccines can be administered, but the immune response may be diminished. Patients should complete all necessary vaccinations before initiating treatment to ensure optimal immune protection.
- There is limited data on the use of this medicinal product during pregnancy and breastfeeding. It should only be used if the potential benefits outweigh the risks. Pregnant or breastfeeding women should discuss the risks with their healthcare provider before starting treatment.
EBGLYSS (lebrikizumab-lbkz) injection can be imported by patients or government hospitals on the name of the patients only.
- A valid prescription from a qualified doctor.
- Patients diagnostic reports
- Patient ID proof (issued by the government of India)
- A valid prescription from the Doctor
- Import permit if applicable
- On availability of Ebglyss in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune etc.)
- On availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait, Iraq, Saudi Arabia, and the UAE).
- Medicine Price.
- Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
- Ensuring 100% transparency.
What is the Generic Name for the trade name drug Ebglyss®?
What is the Manufacturer’s Name of Ebglyss®?
Is Ebglyss® approved by the FDA?
What is the dosage and form of Ebglyss® supplied?
What are the most common side effects of Ebglyss®?
How much does Ebglyss® 250 mg/2 mL cost in India?
Is it safe to buy Ebglyss® 250 mg/2 mL injections online in India?
What are the storage conditions of Ebglyss® 250 mg/2 mL injections?
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.